Egalet receives FDA tentative approval for expanded label for ARYMO® ER (morphine sulfate)
Egalet announced the FDA has granted tentative approval for an expanded label for ARYMO ER (morphine sulfate) extended-release tablets C-II for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. December 15, 2017